Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843110 | 1.00 | PTPN1 (0.54) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL29500417 | 1.00 | PTPN1 (0.54) | PTPN1MDM4TP53SLC17A5MDM2 | |
| Catechol SCHEMBL18074826 | 0.99 | PTPN1 (0.53) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL24495215 | 0.91 | PTPN1 (0.52) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL15083325 | 0.91 | MDM2 (0.52) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL14584328 | 0.91 | FOLH1 (0.51) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL24489613 | 0.91 | FOLH1 (0.51) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL2578833 | 0.91 | CA2 (0.51) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL21192400 | 0.91 | PTPN1 (0.52) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL2030857 | 0.91 | FOLH1 (0.51) | PTPN1MDM4TP53SLC17A5MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270949-A2 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | Case Western Reserve University (US) | 2018-01-24 | — | — | EP | claimed |
| CN-107530405-A | Insulin analogs containing glucose-regulated conformational converters | 卡斯西部储备大学 | 2018-01-02 | — | — | CN | claimed |
| WO-2016149222-A2 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-22 | — | — | WO | claimed |
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-10-23 | — | — | US | disclosed |
| EP-3270949-B1 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | UNIV CASE WESTERN RESERVE (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240218041-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | disclosed |
| US-20230399373-A1 | MOLECULAR DESIGNS OF GLUCOSE-RESPONSIVE AND GLUCOSE-CLEAVABLE INSULIN ANALOGUES | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-12-14 | — | — | US | disclosed |
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RAMBAM MED-TECH LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| EP-4232464-A1 | MOLECULAR DESIGNS OF GLUCOSE-RESPONSIVE AND GLUCOSE-CLEAVABLE INSULIN ANALOGUES | The Trustees of Indiana University (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022087385-A1 | MOLECULAR DESIGNS OF GLUCOSE-RESPONSIVE AND GLUCOSE-CLEAVABLE INSULIN ANALOGUES | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-04-28 | — | — | WO | disclosed |
| US-9867869-B2 | Insulin derivatives for diabetes treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-01-16 | — | — | US | disclosed |
| US-20150320837-A1 | INSULIN DERIVATIVES FOR DIABETES TREATMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2015-11-12 | — | — | US | disclosed |
| WO-2014093696-A2 | INSULIN DERIVATIVES FOR DIABETES TREATMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-06-19 | — | — | WO | disclosed |
| US-5098999-A | Amidation of amino acids like dopa for use as adhesives and for treatment of Parkinson*s disease | HITACHI CHEMICAL COMPANY (JP) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RPTOR, PSMG3, MTOR | PTPN1 818/4885MDM4 1267/4885TP53 106/4885 |
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | PSMC1, PSME3, PSMA6 | PTPN1 1971/4885MDM4 1440/4885TP53 595/4885 |
| US-20240218041-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | IAPP, GPR119, INSR | PTPN1 3141/4885MDM4 3707/4885TP53 2602/4885 |
| US-20230399373-A1 | MOLECULAR DESIGNS OF GLUCOSE-RESPONSIVE AND GLUCOSE-CLEAVABLE INSULIN ANALOGUES | IAPP, GPR119, INSR | PTPN1 4421/4885MDM4 4202/4885TP53 1914/4885 |
| US-20150320837-A1 | INSULIN DERIVATIVES FOR DIABETES TREATMENT | IAPP, INSR, IRS1 | PTPN1 939/4885MDM4 1094/4885TP53 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.